Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another?

<b>Background:</b> Kidney transplant recipients (KTRs) are likely to develop severe COVID-19 and are less well-protected by vaccines than immunocompetent subjects. Thus, the use of neutralizing anti–SARS-CoV-2 monoclonal antibodies (mAbs) to confer a passive immunity appears attractive in KTRs. <b>M...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Anais Romero, Charlotte Laurent, Ludivine Lebourg, Veronique Lemée, Mélanie Hanoy, Frank Le Roy, Steven Grange, Mathilde Lemoine, Dominique Guerrot, Dominique Bertrand
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	MDPI AG 2024-02-01
Sarja:	Viruses
Aiheet:	COVID-19 monoclonal antibodies SARS-CoV-2 kidney transplantation
Linkit:	https://www.mdpi.com/1999-4915/16/3/381
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!